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Conclusion: After BMS implantation, stent fracture could have no effect on stent
thrombosis. However, stent fracture after DES implantation could have impact on stent
thrombosis as time passes.
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Background: Implantation of long and multiple overlapping DES in diffusely diseased
vessels, is frequently performed in routine clinical practice. Despite their widespread
use, concerns have been raised regarding DES safety and efficacy for treatment of
diffuse disease or long lesions requiring multiple stent implantation. In this registry,
we assessed the performance of the second generation Resolute Zotarolimus-eluting
stent (ZES) in this specific subgroup of patients.
Methods: From August 2008, 314 patients treated in 10 Italian Centers with >31.5mm
Resolute stent were prospectively followed in the context of the Clinical-Service
program. Comparison with patients receiving <31.5 mm of stents was also
performed.Patients were divided in two groups according to the length of the stent
implanted: group 1[(n=731)Short Stent, SS]: stented segment length≤ 31.5mm; group
2 [(n= 314) Long Stent, LS]: stented segment length >31.5mm. We compare the
incidence of MACE (cardiac death, re-myocardial infarction, TLR ), stent thrombosis
(ST) and target vessel revascularization (TVR) in the two groups.
Results: 314 patients(575 lesions) with a total ZES length >31.5 mm was collected in
the LS group (79% male, 66±10 years, 33% diabetic). The mean follow up was
244±160 days.SS group was composed of 731 patients (77% male, 65±11 years, 30%
diabetic) followed for a mean time of 316±295 days.There was no significant difference
in the overall incidence of MACE among the two groups (5.6% in LS versus 5.7% in
SS, p=ns).The incidence of cardiac death (1.8% vs. 2.5%), acute myocardial infarction
(2.8% vs. 2.6%), TLR (2.4% vs. 2.6%) and TVR (5.5% vs. 6.9%) was similar in the
long and short stent group (p=ns), respectively. No difference was found in ST between
the LS vs. SS groups (definite: 0.6% vs. 0.3%, p=0.37; probable: 0% vs. 1.4%,
p=0.27;early: 0.6% vs. 0.3%, p=ns; late: 0.6% vs. 2% p=ns). Dual antiplatelet therapy
discontinuation before 12 months was similar in the two groups (LS=1.6%, SS=2.9%,
p=ns).
Conclusion: In this multicentre prospective study, implantation of the Resolute ZES
for the treatment of diffuse and long coronary artery disease appears effective and safe.
Multiple or long Resolute stent implantation was associated with an acceptable MACE
rate at mid-to-long term follow-up without a significant increase in the risk of ST.
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Background: Since the approval of Drug-Eluting Stents (DES) in Europe in 2002,
DES have been quickly entering into daily clinical practice even in indications without
data from randomised controlled clinical trials (off-label use). At the European and
World Congress of Cardiology in Barcelona 2006, alarming data were presented on a
worse long-term prognosis following DES implantation compared with BMS. This
resulted in a higher cautiousness for its use with a decrease of DES implantations in
clinical practice.
Methods: Between 2005 and 2008, 47,407 consecutive patients undergoing PCI were
enrolled into the PCI-Registry of the Euro Heart Survey Programme to document
patient characteristics, PCI details and hospital complications in different PCI
indications. We examined the development of DES use over time by splitting the
enrolment period into 6- months periods (Jan-Jun and Jul-Dec) for the years 2005 to
2008 to identify a possible collapse in DES use and its further development following
September 2006.
Results: A total of 22,917 patients underwent elective PCI, 24,090 PCI for ACS. From
the very beginning of the documentation period the use of DES was high with about
60% in elective PCI and about 50% in PCI for ACS. After the presentation of the
alarming data on long-term outcome after DES during the ESC Congress in 2006, the
use of DES significantly decreased to 43% in elective PCI (p<0.01) and to 33% in PCI
for ACS (p<0.01) and remained low since then.
Conclusion: In consecutive patients undergoing elective PCI as well as PCI for ACS
in Europe, the use of DES collapsed after the presentation of alarming data of a worse
long- term prognosis following DES implantation during the ESC-Congress 2006.
Despite re-assuring data on the safety of DES, the use of DES did not recover in clinical
practice in Europe.
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Background: Efficacy and safety data following sirolimus-eluting stent (SES) PCI in
unselected patients at very long-term follow-up (>5 years) are still limited.
Methods: all consecutive patients with significant coronary artery stenosis treated with
PCI and only SES implantation between December 2001 and February 2003 were
analyzed in order to assess the survival-free from major adverse cardiovascular events
(MACE) defined as a composite of death, myocardial infarction (MI) and target vessel
revascularization (TVR) and survival-free from target lesion failure (TLF) defined as
a composite of cardiac death, target vessel-MI (TV-MI) and target lesion
revascularization (TLR).
Results: 447consecutive patients (954 lesions) treated with SES implantation were
treated in the study period. Mean age was 61.9±10.4 years, 399 (89.3%) patients were
male, 99 (22.1%) had diabetes mellitus, and 356 (79.6%) had multi-vessel disease. Of
the 954 lesions treated, 771 (80.8%) were ACC/AHA type B2/C including ostial
(19.5%), bifurcation (18.6%), restenotic (16.2%), chronic total occlusions (9.9%) and
left main (9.1%) lesions. Mean number of stents implanted per patients was 2.03 ±
1.04. Median dual antiplatetlet therapy (DAT) duration was 253 (IQR 162-1197) days.
Clinical follow-up was available at 8 years in 403 eligible patients (90.2%). The
cumulative incidence of events at 8 years was: death 15.7% (65 patients), cardiac death
8.3% (34 patients); MI 7.9% (32 patients), TV-MI 6.2% (25 patients) and TVR 41.2%
B73JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/POSTER/Bioabsorbable, Drug-Eluting, and Bare Metal Stent Studies
P
O
S
T
E
R
S
www.JACC.TCTAbstracts2011
TUESDAY, NOVEMBER 8, 2011, 8:00 AM - 10:00 AM
(170 patients). Angiographic follow-up was performed at a median of 268 (IQR 178-
303) days from the index procedure for 753 (78.9%) lesions. In-stent restenosis rate
was 24.4% of whom 2.8% were defined as late. The cumulative TLR incidence was
31.4% (130 patients). The 8-year survival-free from MACE was 50.7% while survival-
free from TLF was 92.2%. ARC defined definite/probable ST occurred in 12 patients
(cumulative incidence of 3.1%) of whom 2 sub-acute, 1 late and 9 very late. Of these
2 occurred while on DAT and 9/12 patients survived the event.
Conclusion: the implantation of SES in unrestricted clinical practice resulted in a high
8-year survival-free from TLF showing maintained efficacy and efficiency of this
device at very long-term follow-up. MACE attrition remained high mainly due to TVR
as expected in such a complex cohort.
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Background: Chronic total occlusion (CTO) intervention is still challenging because
of the limited procedural success rate and higher target failure. The detailed safety and
efficacy data of CTO intervention in the drug-eluting stent (DES) era from multi center
real world registry are still limited.
Methods: Korean multicenter retrospective CTO registry was collected from Jan 2007
to Dec 2009 and a total of 2961 patients (pts) underwent CTO intervention with DESs
were enrolled from 26 major percutaneous coronary intervention (PCI) centers by
filling out retrospective case report form (CRF). Baseline clinical and procedural
characteristics, major clinical outcomes up to 12 months were evaluated.
Results: The baseline clinical characteristics showed that male were in 73.9%, previous
myocardial infarction (MI) 83.5%, previous PCI 20.5%, hypertension 60.0%, diabetes
35.0%, hyperlipidemia 31.1% and current smoker 26.3%. Myocardial viability test
was done in 13.1% and pre-PCI cardiac CT was done in 15.6%. Lesion distribution
was as follows; RCA 43.0%, LAD 40.6%, LCX 21.8%, LM 0.6% and Ramus 0.4%.
Angiographically unfavorable morphology was in 64.5%. Anterograde approach was
attempted in 96.5% and IVUS guided intervention was done in 25.4%. More than 90%
of the pts received DESs; Sirolimus-eluting stents (SES) 35%, Paclitaxel-ES (PES)
26%, Zotarolimus-ES (ZES) 22%, Everolimus-ES (EES) 11% and others 6%. Overall
procedural success rate was 81.6% (2074/2538 pts) At 12 months, total death was 2.9%,
any MI 1.3%, target lesion revascularization (TLR) 4.4%, target vessel
revascularization (TVR) 7.0%, TLR-major adverse cardiac events (MACEs) 6.5%,
TVR-MACE 10.3% and MACCE 10.6% (Table).
Conclusion: The success rate, safety profile and 12-month cumulative clinical
outcomes of Korean CTO pts following PCI with DES were favorable. Long-term
follow up with larger study population will be necessary to elucidate final conclusion.
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Background: Although the recanalization of chronic total occlusion (CTO) lesions in
native coronary arteries no doubt represents one of the most technically challenging
of interventional procedures, a recently developed hydrophilic floppy wire can allow
us to cross the CTO lesion without any complicated techniques. Multi-slice computed
tomographic coronary angiography (CTCA) provides noninvasive evaluation of the
coronary artery by visualizing vessel trajectory and morphological features at the
occluded site.
Methods: The aim of this study was to evaluate the value of CTCA in predicting the
micro channels most likely to achieve successful guidewire crossing prior to CTO PCI.
Results: Successful wiring with a single soft wire using the antegrade approach was
achieved in 111 lesions (59.4%). Compared to the Control group, the Single group had
more micro contrast infiltration and less stump morphology at the distal end (Table).
Conclusion: Micro contrast Infiltration at the occluded portion and stump morphology
(distal) on CTCA are significant predictors for successful wiring with a single soft
wire. These findings indicate that CTCA could provide practical information to
determine the outcomes of CTO-PCI.
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Background: There are few studies which evaluate the influence of stent length on
long-term clinical outcomes of sirolimus-eluting stent (SES) implantation for chronic
total occlusion (CTO).
Methods: A total of 533 patients with 569 lesions underwent successful CTO
recanalization with SES Implantation between December 2002 and December 2007.
Major adverse cardiac events (MACE) are composed of cardiac death, myocardial
infarction, and target vessel revascularization (TVR). Stent thrombosis (ST) was
identified using the Academic Research Consortium definition. A stratified analysis of
MACE and ST at five years was performed based on the stent length: intermediate
stent group, ≤70 mm and long stent group, >70 mm.
Results: The median follow-up duration was 4.4 years. Kaplan-Meier estimates of
TVR at 5 years were 27.1% vs. 38.1%, p<0.01 (figure). The Cox proportional hazard
analysis identified chronic hemodialysis (adjusted hazard ratio [HR]: 8.77, 95%
confidence interval [CI]: 3.97 to 19.37, p<0.01) and reduced left ventricular ejection
fraction (HR: 2.87, 95%CI: 1.31 to 6.30, p=0.01) as independent predictors of cardiac
death, but not stent length. There was no significant difference in the definite or
probable ST between the two groups (0.6% vs. 2.7%, p=0.08).
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